COVID-19: Drug Targets and Potential TreatmentsCarmen Gil, Ana Martı́nez, Tiziana Ginex et al.|Journal of Medicinal Chemistry|2020Cited by 469
Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseasesVanesa Nozal, Ana Martı́nez|European Journal of Medicinal Chemistry|2018Cited by 47
Protein kinase inhibitors for amyotrophic lateral sclerosis therapyValle Palomo, Ana Martı́nez, Vanesa Nozal et al.|British Journal of Pharmacology|2020Cited by 47
TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral SclerosisValle Palomo, Ana Martı́nez, Carlota Tosat‐Bitrián et al.|ACS Chemical Neuroscience|2019Cited by 46
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis TherapyVanesa Nozal, Ana Martı́nez, Marta Gómez‐Almería et al.|Journal of Medicinal Chemistry|2022Cited by 45